anti-CD20 chimeric antigen receptor

Anti-CD20 chimeric antigen receptor (CAR) therapy is a form of adoptive cellular immunotherapy where T cells are genetically engineered to express a synthetic receptor targeting the CD20 antigen, a protein primarily found on the surface of B cells. This modality is primarily developed for the treatment of B-cell malignancies, such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), particularly in patients who have relapsed or are refractory to anti-CD20 monoclonal antibodies like rituximab. The CAR construct typically consists of an extracellular single-chain variable fragment (scFv) derived from an anti-CD20 antibody, a transmembrane domain, and intracellular signaling domains (e.g., CD3-zeta and costimulatory domains like 4-1BB or CD28) that trigger T-cell activation and tumor cell lysis upon binding to CD20.

Other names

CD20 CAR-TCD-20 CAR-TCD 20 CAR-Tanti-CD20 CAR-Tanti-CD-20 CAR-Tanti-CD 20 CAR-TCD20-directed CAR-T cell therapyCD-20-directed CAR-T cell therapyCD 20-directed CAR-T cell therapy